BLFS - バイオライフ・ソリュ―ションズ （BioLife Solutions Inc.） バイオライフ・ソリュ―ションズBLFSのチャート
BLFSの企業情報
| symbol | BLFS |
|---|---|
| 会社名 | Biolife Solutions Inc （バイオライフ・ソリュ―ションズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Electromedical_Electrotherapeutic Apparatus |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 BioLife Solutions Inc. (BioLife) is engaged in the developing manufacturing and marketing a portfolio of biopreservation tools and services for cells tissues and organs including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers. The Company's product offerings include hypothermic storage and cryopreservation freeze media products for cells tissues and organs; generic blood stem cell freezing and cell thawing media products; custom product formulation and custom packaging services; cold chain logistics services incorporating precision thermal packaging products and cloud-hosted Web applications and contract aseptic manufacturing formulation fill and finish services of liquid media products. Its products include HypoThermosol FRS CryoStor BloodStor Cell Thawing Media PrepaStor and biologistex cold-chain management service. バイオライフ・ソリュ―ションズは、米国のバイオプリザベ―ション製品メ―カ―。細胞や組織用の低体温貯蔵と凍結保存ソリュ―ションの特許を所有し、製品の開発、製造、販売を手掛ける。バイオバンク、創薬、再生医療、毒性試験、診断市場を対象に主要製品HypoThermosol、CryoStor、BloodStor、SAVSUなどを提供する。 BioLife Solutions is a leading supplier of cell and gene therapy bioproduction products and services. Its products and services portfolio includes its proprietary CryoStor® freeze media, HypoThermosol® shipping and storage media, ThawSTAR® family of automated, water-free thawing products, evo® cold chain management system, and Custom Biogenic Systems high capacity storage freezers and SciSafe biologic storage services. |
| 本社所在地 | 3303 Monte Villa Parkway Suite 310 Bothell WA 98021 USA |
| 代表者氏名 | Raymond Wayne Cohen レイモンドウェインコーエン |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 425-401-1400 |
| 設立年月日 | 1987年 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 40人 |
| url | www.biolifesolutions.com |
| nasdaq_url | https://www.nasdaq.com/symbol/blfs |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 1.49751 |
| 終値（lastsale） | 12.95 |
| 時価総額（marketcap） | 231679151.9 |
| 時価総額 | 時価総額（百万ドル） 236.50950 |
| 売上高 | 売上高（百万ドル） 15.09058 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 236.45623 |
| 当期純利益 | 当期純利益（百万ドル） -0.14596 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 BioLife Solutions Inc revenues increased 83% to $9M. Net income applicable to common stockholders totaled $943K vs. loss of $1.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Interest expense decrease of 99% to $2K (expense) Loss from equity-method investment in SA decrease of 35% to $321K (expense). |
BLFSのテクニカル分析
BLFSのニュース
iVexSol Closes $23.8M Series A-3 Financing 2023/01/26 14:44:27 FinSMEs
iVexSol, a Lexington, MA-based technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), raised $23.8m in Series A-3 funding. New investors Bristol Myers Squibb (NYSE: BMY), Charles River Laboratories (NYSE: CRL) and Asahi Kasei Medical, a division of Asahi Kasei (NYSE: AHKSY), joined existing investors Casdin Capital and BioLife Solutions (Nasdaq: BLFS) to close […] The post iVexSol Closes $23.8M Series A-3 Financing appeared first on FinSMEs .
How should investors view BioLife Solutions Inc. (BLFS)? 2023/01/18 14:24:00 US Post News
BioLife Solutions Inc. (NASDAQ:BLFS) closed Tuesday at $24.95 per share, up from $23.54 a day earlier. While BioLife Solutions Inc. has overperformed by 5.99%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BLFS fell by -18.46%, with highs and lows ranging from $31.12 to $10.40, whereas […]
BioLife Solutions guides Q4 and FY22 revenue above consensus, initiates FY23 guidance 2023/01/09 14:32:01 Seeking Alpha
BioLife Solutions (BLFS) reported preliminary and unaudited Q4 revenue of $44.M, an increase of 19% Y/Y, vs consensus of $43.42M
BioLife Solutions Announces 2022 Fourth Quarter and Full Year Preliminary Unaudited Revenue and Introduces 2023 Revenue Guidance 2023/01/09 13:05:00 PR Newswire
Record quarterly revenue of $44.4 million up 19% over Q4 2021 with Cell Processing Platform revenue growth of 37% Record full year revenue of $161.9 million up 36% over 2021, with organic revenue growth of 38% and Cell Processing Platform revenue growth of 53% Initial revenue guidance for…
BioLife Solutions: Inventory Movement A Key Benchmarking Factor, Retain Hold (BLFS) 2023/01/05 22:00:27 Seeking Alpha
BioLife Solutions, Inc. guidance narrowed for full-year estimates. Click here to see why we continue to rate BLFS stock as a hold.
Biolife Solutions Inc (BLFS) CEO Michael Rice Sold $1.3 million of Shares 2021/11/05 14:15:05 GuruFocus
Related Stocks: BLFS ,
BioLife Solutions to Report Third Quarter 2021 Financial Results and Provide Business Update on November 11, 2021 2021/11/04 12:03:00 PR Newswire
BOTHELL, Wash., Nov. 4, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company''s third quarter 2021 financial
Geode Capital Management LLC Purchases 133,124 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) 2021/11/01 09:10:44 Dakota Financial News
Geode Capital Management LLC increased its position in BioLife Solutions, Inc. (NASDAQ:BLFS) by 37.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 488,006 shares of the medical equipment providers stock after acquiring an additional 133,124 shares during the quarter. Geode Capital Management LLC owned []
BioLife Solutions Inc. (NASDAQ:BLFS) Up 47.19% Since 52-Week Low; YTD Rose 33.24% Heres What You Need To Do 2021/10/30 15:30:00 Marketing Sentinel
BioLife Solutions Inc. (NASDAQ:BLFS)s traded shares stood at 0.56 million during the last session, with the companys beta value hitting 1.47. At the close of trading, the stocks price was $53.15, to imply an increase of 4.73% or $2.4 in intraday trading. The BLFS shares 52-week high remains $60.67, putting it -14.15% down since that BioLife Solutions Inc. (NASDAQ:BLFS) Up 47.19% Since 52-Week Low; YTD Rose 33.24% Heres What You Need To Do Read More »
BioLife Solutions, Inc. (NASDAQ:BLFS) Insider Sells $725,957.40 in Stock 2021/10/28 03:16:41 Dakota Financial News
BioLife Solutions, Inc. (NASDAQ:BLFS) insider Karen A. Foster sold 16,332 shares of the stock in a transaction that occurred on Monday, October 25th. The stock was sold at an average price of $44.45, for a total value of $725,957.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is []